Anticoagulation Profile in Pregnant Women Treated with Three Times a Day of Low Molecular Weight Heparin (LMWH)

Launched by UNIVERSITY OF CALIFORNIA, IRVINE · Apr 22, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how a medication called Lovenox, which helps prevent blood clots, can be given more effectively to pregnant women. Pregnant women are at a higher risk for blood clots, and current recommendations suggest taking Lovenox twice a day. However, many women may not get the right amount of the medication during the day. This study is exploring whether giving Lovenox three times a day could help maintain more consistent levels of the medication in the body, potentially reducing the risk of clots.

To participate in this trial, women must be at least 18 years old and have a single pregnancy where they need Lovenox for blood clot prevention. Unfortunately, women who are pregnant with multiples, under 18, have certain medical conditions like a history of Heparin Induced Thrombocytopenia (a specific reaction to heparin), or have an allergy to Lovenox cannot take part. If eligible, participants will take Lovenox three times a day and will be monitored throughout the study to see how well this dosing schedule works.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Nulliparous or multiparous women with single intrauterine pregnancies who require therapeutic low molecular weight heparin during their pregnancy.
• • Participants must be age 18 or older.
• Exclusion Criteria:
• • Women with multiples.
• • Women less than age 18
• • History of Heparin Induced Thrombocytopenia (HIT)
• • Allergy to enoxaparin